At a glance
ClinicalIndex Comparison Record- ✓Age >18 years
- ✓Histologically or cytologically confirmed hepatocellular carcinoma
- ✓Bidimensional measurable disease on CT or MRI not exceeding 50% of liver parenchyma
- ✓Clinical candidate for chemoembolization with at least one lesion >3 cm and no lesion >15 cm in longest diameter
- ✕Previous liver transplantation
- ✕Fibrolamellar histology
- ✕Prior antiangiogenesis therapy
- ✕Extrahepatic disease present
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Of rhuMAb VEGF (BEVACIZUMAB) In Patients With Hepatocellular Carcinoma Receiving Chemoembolization
In Brief
A Phase 2 clinical trial evaluating bevacizumab for Liver Cancer. Completed, enrolled 30 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, cisplatin, and mitomycin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. Monoclonal antibodies, such as bevacizumab, can kill any tumor cells that are left after chemoembolization by blocking their ability to grow and spread. PURPOSE: This randomized phase II trial is studying to see if chemoembolization followed by bevacizumab works better than chemoembolization alone in treating patients who have liver cancer that cannot be removed with surgery.
Study Details
Timeline
Interventions
Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization. Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose.